Tag: site specific conjugation

Over the past decade, site-specific chemical conjugation has emerged as a promising strategy to produce antibody-drug conjugates (ADCs) in the field of oncology [1]. Daiichi-Sankyo's chemical conjugation method, which uses high drug-to-antibody ratio (DAR) technology, was approved by the U.S. Food and Drug Administration as the first site-specific ADC (fam-trastuzumab-deruxtecan-nxki; Enhertu® | Daiichi Sankyo and AstraZeneca).

Antibody drug conjugates (ADCs) are touted for their ability to site selectively deliver a small molecule chemotherapeutic directly to a tumor cell, bypassing off target side effects from systemic circulation. To date, eleven ADCs have been FDA approved in the United States and >200 more in the clinical pipeline (clinicaltrials.gov).

Suzhou (China-) based CStone Pharmaceuticals and LegoChem Biosciences have signed a global licensing agreement in which CStone acquires exclusive rights for development and commercialization...

Privately-owned Swiss biotech NBE-Therapeutics and Exelixis, confirmed a new partnership to discover and develop multiple antibody-drug conjugates (ADCs) for applications within oncology and hematology....

During the 16th Annual PEGS Boston Virtual Conference & Expo, which took place between August 31 – September 4, 2020, Gregory Bleck, Ph.D., Global...

Boston-based BrickBio has demonstrated its ability to insert unnatural amino acids (UAAs; called "attachment bricks"), at any site, specifically, within a protein or antibody...

Patients being treated for cancer may often benefit from a combination of systemic cancer chemotherapies. The rationale for the combination of multiple anti-cancer therapies...

Abstract The continuing advancements in bioconjugate medicines from delivery of potent cytotoxins to vaccine-, oligonucleotide-, radionuclide-, immunomodulator- and check-point inhibitor-conjugates, can start to address the...

The Netherlands-based biotech company Synaffix, which has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates or ADCs, launched of a...

Earlier this year, a record number of 2,300 delegates attended the 13th edition of the "PEGS: The Essential Protein Engineering Summit," held May 1...